Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

4,215

datasets available to search

ShareScore release 0.9.0

Dataset results

4,215 results for “high risk”

Learn how ShareScore rates datasets ↗

dryad36/100

Data from: Are Mediterranean marine threatened species at high risk by climate change?

Rapid anthropogenic climate change is driving threatened biodiversity one step closer to extinction. Effects on native biodiversity are determined by an interplay between species' exposure to climate change and their specific ecological and life-history characteristics that render them even more susceptible. Impacts on biodiversity have already been reported; however, a systematic risk evaluation of threatened marine populations is lacking. Here, we employ a trait-based approach to assess the risk of 90 threatened marine Mediterranean species to climate change, combining species' exposure to increased sea temperature and intrinsic vulnerability. One-quarter of the threatened marine biodiversity of the Mediterranean Sea is predicted to be under elevated levels of climate risk, with various traits identified as key vulnerability traits. Climate risk, vulnerability and exposure hotspots are distributed along the Western Mediterranean, Alboran, Aegean, and Adriatic Seas. At each Mediterranean marine ecoregion, 21% to 31% of their threatened species have high climate risk. All Mediterranean Marine Protected Areas host threatened species with high risk to climate change, with 90% having a minimum of 4 up to 19 species of high climate risk, making the objective of a climate-smart conservation strategy a crucial task for immediate planning and action. Our findings aspire to offer new insights for systematic, spatially strategic planning and prioritization of vulnerable marine life in the face of accelerating climate change.

opencc-zeroJan 2023View details →

dryad36/100

The effectiveness and safety of intensive lipid-lowering with different Rosuvastatin-based regimens in patients at high risk: A nonblind, randomized, controlled trial

Background: Statin alone or nonstatins as add-ons have been introduced to intensive low-density lipoprotein cholesterol (LDL-C) lowering therapy in patients at high cardiovascular disease (CVD) risk. The purpose of this study was to evaluate the effectiveness and safety of different statin-based regimens for patients at high risk. Methods: Three hundred patients at high CVD risk were randomly assigned to the statin group (Rosuvastatin 20mg/d), statin_EZ group (Rosuvastatin 10mg/d + ezetimibe 10mg/d), statin_pcsk group (Rosuvastatin 10mg/d + alirocumab 75mg/2weeks) or combine3 group (Rosuvastatin 10mg/d + ezetimibe 10mg/d + alirocumab 75mg/2weeks). The primary outcome measure was cholesterol levels (LDL-C, total cholesterol (TC) triglycerides (TGs), and high-density lipoprotein cholesterol (HDL-C)) after 24 weeks of follow-up. The secondary outcome measures were safety markers and the proportion of patients who achieved the < 70 mg/dL (1.8 mmol/L) LDL-C target. A logistic regression model was performed to explore the factors affecting lipid target achievement. Results: The TC and LDL-C levels after treatment were significantly different among the four groups (p < 0.05). The levels in both the combine3 group and the statin_pcsk9 group were significantly lower than those in the statin group and the statin_EZ group (p < 0.05), but there was no significant difference between the combine3 group and the statin_pcsk9 group. The incidence of adverse events in the four groups was low. Body mass index (BMI) and hypertensive status were related to target achievement. Conclusion: The combination of a statin and a PCSK9 inhibitor was safe and more effective for the treatment of high-risk CVD patients, while the addition of ezetimibe was unable to significantly lower lipid levels any further. The rate of achieving the target was higher in patients with hypertension and a low BMI.

opencc-zeroMar 2023View details →

dryad36/100

Polymorphisms in genes related to inflammation and endothelial function in the high-risk stroke population

Aim: To investigate incidence of ischemic stroke and other vascular events during a 4.7-year follow-up in the high-risk stroke population, and to identify the associations of the 19 single nucleotide polymorphisms (SNPs) in genes related to inflammation and endothelial function and interaction among these SNPs with outcomes. Methods: According to the China National Stroke Screening Survey programme, we performed this multi-center community-based sectional survey and prospective cohort study in the Sichuan of southwestern China from May 2015 to January 2020. Eight communities were randomly selected in Sichuan, and the residents in each community volunteered to participate in a face-to-face survey. The 19 SNPs in genes related to endothelial function and inflammation were measured in the high-risk stroke population. All subjects in high-risk stroke populations were followed-up for 4.7 years after the face-to-face survey. The primary outcome was a new ischemic stroke; the secondary outcome was a composite of new vascular events. Results: A total of 2893 high-risk stroke population, 2698 (93.3%) completed a 4.7-year follow-up. Outcomes occurred in 192 (7.1%) subjects (118 [4.4%] new ischemic stroke, 24 [0.9%] hemorrhagic stroke, 53 [2.0%] myocardial infarction, and 33[1.2%] death) in the 2698 high-risk stroke population. There were significant differences in genotype distribution of TNF rs3093662, IL6R rs4845625 and TLR4 rs752998 between subjects with and without outcomes by univariate analyses. Generalized multifactor dimensionality reduction (GMDR) analysis showed that there was a significant gene-gene interaction among the 19 SNPs, the best model for outcomes was interaction among IL6R rs4845625, TLR4 rs1927911 and HABP2 rs932650 (P = 0.004). The high-risk interactive genotypes among the 3 SNPs were independently associated with a higher risk for new ischemic stroke (OR = 2.187, 95% CI: 1.256–5.374, P<0.001) and total vascular events (OR = 2.382, 95% CI: 1.423–5.894, P<0.001) after adjustment with covariates. Conclusion: The incidence of ischemic stroke and other vascular events was found to be very high in the high-risk stroke population. There were associations of specific SNPs in genes related to inflammation and endothelial function with outcomes. The high-risk interactive genotypes among IL6R rs4845625, TLR4 rs1927911 and HABP2 rs932650 were independently associated with a higher risk for new ischemic stroke and other vascular events. These findings are expected to provide new strategies for prevention of ischemic stroke and other vascular events.

Find research datasets worth reusing

Dataset results

Data from: Are Mediterranean marine threatened species at high risk by climate change?

The effectiveness and safety of intensive lipid-lowering with different Rosuvastatin-based regimens in patients at high risk: A nonblind, randomized, controlled trial

Polymorphisms in genes related to inflammation and endothelial function in the high-risk stroke population

HPV Vaccine Immunity in High-risk Women

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

Assess Incidence of Deep Vein Thrombosis(DVT)Following Administration of Recombinant Human Antithrombin (rhAT) to Hereditary Antithrombin(AT) Deficient Patients in High Risk Situations.

Anticaries Effect of Xylitol,Probiotic and Chlorhexidine Mouth Rinses Among Individuals at High Risk

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

Effectiveness and Safety Study of Early add-on of Ezetimibe With Atorvastatin in Very High-risk Patients

Hormone Suppression and Radiation Therapy for 6 Months With/Without Docetaxel for High Risk Prostate Cancer

Genistein in Preventing Breast Cancer in Women at High Risk for Breast Cancer

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

Study Of Weight-Based Versus Standard Dose Enoxaparin Thromboprophylaxis In High-Risk Hospitalized Cancer Patients

SGLT-2 Inhibitor and Myocardial Perfusion, Function and Metabolism in T2 DM Patients at High Cardiovascular Risk

Pembrolizumab + Lenalidomide Post Autologous Stem Cell Transplant (ASCT) in High-risk Multiple Myeloma (MM)

Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness

Chemotherapy After Prostatectomy (CAP) For High Risk Prostate Carcinoma

Comparison of HD Chemotherapy Followed by Auto-transplant and R-CHOP in High Risk Patients With DLBCL.

Oral Islatravir (MK-8591) Once-Monthly as Preexposure Prophylaxis (PrEP) in Men and Transgender Women Who Are at High Risk for HIV-1 Infection (MK-8591-024)

A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH

Understand access before you commit

Allen Brain Atlas

Annotated Behaviour and Observability Dataset (ABODe)

DANDI Archive for NWB datasets

International Brain Laboratory public data

OpenNeuro